Pasithea Therapeutics regains Nasdaq minimum bid price compliance

Pasithea Therapeutics Corp.

Received Nasdaq deficiency notice on June 23, 2025 for failing $1.00 minimum bid price rule 5550(a)(2).
Compliance deadline was December 22, 2025; on December 12, 2025 Nasdaq confirmed compliance.
Common stock (KTTA) maintained closing bid at or above $1.00 for sufficient consecutive business days.
Nasdaq notified company that the bid price deficiency matter is now closed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.